AbbVie Inc. $ABBV Shares Acquired by Wealth Alliance Advisory Group LLC

Wealth Alliance Advisory Group LLC grew its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 30.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,161 shares of the company's stock after purchasing an additional 3,047 shares during the quarter. Wealth Alliance Advisory Group LLC's holdings in AbbVie were worth $2,443,000 at the end of the most recent reporting period.

• As the Market Rotates, This Healthcare ETF Is Leading the Way

Several other hedge funds and other institutional investors have also recently bought and sold shares of ABBV. Brighton Jones LLC raised its stake in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock worth $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock worth $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Siemens Fonds Invest GmbH raised its stake in AbbVie by 197.6% during the 4th quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company's stock worth $32,000 after acquiring an additional 119,141 shares in the last quarter. Sentinus LLC raised its stake in AbbVie by 1.5% during the 4th quarter. Sentinus LLC now owns 15,788 shares of the company's stock worth $2,805,000 after acquiring an additional 239 shares in the last quarter. Finally, Toronto Dominion Bank raised its stake in AbbVie by 10.4% during the 4th quarter. Toronto Dominion Bank now owns 770,392 shares of the company's stock worth $136,896,000 after acquiring an additional 72,515 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Bank of America lifted their price target on shares of AbbVie to $204.00 and gave the stock a "hold" rating in a research note on Monday, June 9th. Wall Street Zen downgraded shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Guggenheim raised their price objective on shares of AbbVie from $216.00 to $227.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Daiwa America raised shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 7th. Finally, Daiwa Capital Markets raised shares of AbbVie from a "neutral" rating to an "outperform" rating and set a $214.00 price objective on the stock in a research report on Thursday, August 7th. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of "Moderate Buy" and a consensus target price of $217.10.

• AbbVie Stock Eyes Breakout as Pipeline and Profits Grow

Read Our Latest Research Report on ABBV

Insider Activity

In other news, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares of the company's stock, valued at $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the completion of the sale, the executive vice president directly owned 58,247 shares in the company, valued at approximately $11,562,611.97. The trade was a 18.58% decrease in their position. The disclosure for this sale can be found here. 0.25% of the stock is owned by insiders.

AbbVie Stock Down 0.8%

• 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

Shares of NYSE:ABBV opened at $218.40 on Friday. The company has a market cap of $385.82 billion, a price-to-earnings ratio of 104.00, a PEG ratio of 1.42 and a beta of 0.53. The firm's 50-day simple moving average is $200.25 and its 200-day simple moving average is $194.52. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $221.76.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). The firm had revenue of $15.42 billion during the quarter, compared to analysts' expectations of $14.93 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm's revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.65 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Wednesday, October 15th will be issued a $1.64 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.0%. AbbVie's payout ratio is presently 312.38%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Featured Articles

• Five stocks we like better than AbbVie
• Low PE Growth Stocks: Unlocking Investment Opportunities
• Ride the Luxury Retail Wave with These 3 High-End Brand Stocks
• How to Invest in Tech Stocks and Top Tech Stocks to Consider
• Wall Street Quietly Bets Big on These Chinese Tech Giants
• How to Read Stock Charts for Beginners
• Meta's $600B U.S. Investment: Bearish or Bullish for Shares?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here